Peer2Peer: The Podcast

Is the Future of Ophthalmology Shaped by Digital Innovation?

Dr Rosenberg & Dr Wiley unveil the unexplored: ophthalmologists are just scratching the surface with digital advancements.
 
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. Not all Rayner products are available in all countries.
© 2023 Rayner Group, all rights reserved. Rayner, RayPRO and RayOne are proprietary marks of Rayner. All other trademarks are property of their respective owners. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539

Balancing Quantity and Quality of Vision at the Rayner 2023 ESCRS Symposium

In this episode, we’re looking back at the 2023 Rayner Symposium at the European Society of Cataract and Refractive Surgeons in Vienna with Professor Graham Barrett, Dr Damien Gatinel, Professor Oliver Findl and Mr Allon Barsam as they discuss Balancing Quantity and Quality of Vision with Advanced Technology IOLs.
 
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. Not all Rayner products are available in all countries.
© 2023 Rayner Group, all rights reserved. Rayner, RayPRO and RayOne are proprietary marks of Rayner. All other trademarks are property of their respective owners. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539

Highlights from the 2023 AUSCRS EMV Symposium

This episode features a series of presentations and insightful discussions that took place at the 2023 Australian Society of Cataract and Refractive Surgeons Congress about EMV and EMV Toric. Join leading ophthalmologists Prof Graham Barrett, Dr Filomena Ribeiro, Dr Karl Stonecipher, Dr Damien Gatinel, Dr Georgia Cleary, Dr Dean Corbett, and Dr Brian Harrisberg as they discuss patient counseling and outcomes and more.
 
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. Not all Rayner products are available in all countries.
© 2023 Rayner Group, all rights reserved. Rayner, RayPRO and RayOne are proprietary marks of Rayner. All other trademarks are property of their respective owners. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539

Special Episode: Rayner ESCRS 2023 Preview

Rayner’s Vice President of Marketing, Chris Willis, is joined by his colleagues European Marketing Director, Tim Brown, and Medical Communications Manager, Anne Nestor, for this special episode of Peer2Peer: the Podcast. In a break from the usual surgeon-led programming they discuss Rayner’s plans for the upcoming ESCRS 2023 congress in Vienna including an expansive scientific program, two new and exciting digital launches, and more.
 
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. Not all Rayner products are available in all countries.
© 2023 Rayner Group, all rights reserved. Rayner, RayPRO and RayOne are proprietary marks of Rayner. All other trademarks are property of their respective owners. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539

Insights from AECOS Summer 2023

Recorded at AECOS, Dr Paul Singh, Dr Arjan Hura and Dr Karolinne Rocha delve into the recent advancements in ophthalmic technology. Their conversation covers the application of RayOne EMV for enhanced monovision, the importance of tracking patient-reported outcomes using RayPRO, and the role of HASA OPTIX premium, single-use instruments in promoting efficiency within the operating room.
 
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. Not all Rayner products are available in all countries.
© 2023 Rayner Group, all rights reserved. Rayner and RayOne are proprietary marks of Rayner. All other trademarks are property of their respective owners. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539

OMIDRIA Special Ep. 4: From Trial to OMIDRIA on board for Every Surgery: Experts Share Why

In the last episode of ‘Peer2Peer: The Podcast’, OMIDRIA®(phenylephrine and ketorolac intraocular solution) 1%/0.3% series, the host, Dr Arjan Hura, shares a conversation with Dr. William Wiley from the Cleveland Eye Clinic about implementing OMIDRIA into clinical practice. The discussion dives into their early initial experiences with OMIDRIA through to today where it is employed in all of their cataract procedures.
 
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.
Rayner, the Rayner logo, OMIDRIA, and the OMIDRIA logo are proprietary marks of Rayner. © 2023 Rayner Group, all rights reserved. US-OM-2300033 07/23
 
IMPORTANT SAFETY INFORMATION 
OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA.

OMIDRIA Special Ep.3: Performance and Clinical Outcomes of OMIDRIA in Cataract Surgery

This episode of ‘Peer2Peer: The Podcast’, focuses on clinical performance and results from studies conducted with OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%.  in cataract surgery. The episode, featuring Dr. Denise Visco and Dr. Steven Silverstein, highlights the potential advantages of OMIDRIA in cataract surgery shown by rigorous clinical trials, including improved patient compliance and reduced reliance on pain medications, without increasing the risk of complications.
 
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner or other  products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.
 
Rayner, the Rayner logo, OMIDRIA, and the OMIDRIA logo are proprietary marks of Rayner. © 2023 Rayner Group, all rights reserved. US-OM-2300032 07/23
 
IMPORTANT SAFETY INFORMATION 
OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA.

OMIDRIA Special Ep. 2: Using OMIDRIA for Mitigating Risk in Cataract Surgery

In this second episode of ‘Peer2Peer: The Podcast’ focused on OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3, host Dr Arjan Hura, discusses the use of OMIDRIA with Dr. Cathleen McCabe and Dr. Neda Shamie. They highlight the challenges faced by surgeons who suffer from high workloads and how OMIDRIA can help mitigate some of the risks associated with stress in case of complications. Additionally, they explain the benefits of using OMIDRIA with high-risk patients, and the reasons why they often apply it in less complicated cases as well.
 
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.
 
Rayner, the Rayner logo, OMIDRIA, and the OMIDRIA logo are proprietary marks of Rayner. © 2023 Rayner Group, all rights reserved. US-OM-2300031 07/23
 
IMPORTANT SAFETY INFORMATION 
OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA: https://www.omidriahcp.com/documents/8/OMIDRIA-Prescribing-Information.pdf
 

OMIDRIA Special Ep. 1: An OMIDRIA Overview

This episode of ‘Peer2Peer: The Podcast’ is the first from a series of four episodes dedicated to OMIDRIA®(phenylephrine and ketorolac intraocular solution) 1%/0.3%. Dr Arjan Hura, together with top surgeons Gary Foster, Rebecca Metzinger, Denise Visco, Neda Nikpoor, Inder Paul Singh, Kendall Donaldson, Keith Walter and Mitch Jackson share their thoughts and experience on the use of OMIDRIA in cataract surgery. They highlight the benefits of incorporating OMIDRIA, including an improved surgeon, practice, and patient perioperative experience.
 
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner or other products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.
Rayner, the Rayner logo, OMIDRIA, and the OMIDRIA logo are proprietary marks of Rayner. © 2023 Rayner Group, all rights reserved. US-OM-2300030 07/23
 
IMPORTANT SAFETY INFORMATION 
OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA: https://www.omidriahcp.com/documents/8/OMIDRIA-Prescribing-Information.pdf
 

Sustainability in Ophthalmology

Recorded at ASCRS, Professor Oliver Findl and Prof David Chang discuss their collective dedication to promoting sustainability in the field of ophthalmology. They delve into the various initiatives, best practices, and offer a visionary outlook, ultimately illuminating the path toward a future where sustainable eye surgery thrives.
 
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. Not all Rayner products are available in all countries.
© 2023 Rayner Group, all rights reserved. Rayner is a proprietary mark of Rayner. All other trademarks are property of their respective owners. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539